Simple Summary B-cell maturation antigen (BCMA)-directed therapies (BDT) are approved for the treatment of relapsed/refractory multiple myeloma (RRMM). Several treatment modalities exist including chimeric antigen receptor T-cell therapy (CAR-T), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADC). The effectiveness of BCMA-targeting CAR-T and BsAbs has not been compared directly in clinical trial so real-world data provides insight into relative effectiveness. We present retrospectively-collected data comparing CAR-T and BsAbs in patients with RRMM from major US academic institutions. We also explored the impact of prior BDT (BDT-exposed, versus BDT-naïve). CAR-T led to more durable responses in the BDT-naïve setting than BsAbs. Responses to either modality were weaker in the BDT-exposed setting. Furthermore, our data suggest that the washout period and the choice of first BDT impact response rates in the exposed setting. These results highlight the importance of sequencing BDT in RRMM.
BACKGROUND
B-cell maturation antigen (BCMA), a plasma cell-restricted member of the tumor necrosis factor receptor superfamily, has emerged as the premier immunotherapeutic target in Multiple Myeloma (MM).
METHODS
We performed a comprehensive, comparative review of pivotal Phase II and III clinical trials of BCMA-dir...
Massimo Martino, Erica Bilardi, M. Pitea et al.· European Journal of Haematol...· 0 citations
We aimed to evaluate the real-world (RW) efficacy and safety of standard-of-care CART versus TCE therapies in relapsed/refractory myeloma (RRMM), to assess utilization, outcomes, and tolerability of these therapies in a RW oncology in the US. Data were derived from the US-based, electronic health record-derived deident...
Poy Theprungsirikul, Rong Wang, Su-Hsin Chang et al.· European Journal of Haematol...· 0 citations
The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.
P. Caimi, Romano Danesi, G. Iacoboni et al.· Blood reviews· 0 citations
Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether that hierarchy holds in early relapse is unknown. We analyzed randomized phase 3 trials comparin...
Maximilian Merz, J. Souto, P. Voorhees et al.· Journal of Hematology & Onco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.